Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates.
作者信息
Leroux Stéphanie, van den Anker Johannes N, Smits Anne, Pfister Marc, Allegaert Karel
机构信息
Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Neonatal Intensive Care Unit, University Hospital Rennes, Rennes, France.
出版信息
Br J Clin Pharmacol. 2019 May;85(5):865-867. doi: 10.1111/bcp.13899. Epub 2019 Mar 4.
Abstract
摘要
相似文献
1
Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates.万古霉素蛋白结合的成熟变化影响新生儿万古霉素的给药剂量。
Br J Clin Pharmacol. 2019 May;85(5):865-867. doi: 10.1111/bcp.13899. Epub 2019 Mar 4.
2
[Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].[耐甲氧西林金黄色葡萄球菌所致持续性菌血症。治疗不充分的结果]
Enferm Infecc Microbiol Clin. 2009 Jun;27(6):372-3. doi: 10.1016/j.eimc.2008.12.002. Epub 2009 Mar 31.
3
Making the change to area under the curve-based vancomycin dosing.改为基于曲线下面积的万古霉素给药方案。
Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995. doi: 10.2146/ajhp180034. Epub 2018 Oct 17.
4
Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.万古霉素暴露目标的确定和新生儿个体化给药建议：模型指导下的精准给药。
Int J Antimicrob Agents. 2021 Mar;57(3):106300. doi: 10.1016/j.ijantimicag.2021.106300. Epub 2021 Feb 7.
5
Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant Bacteremia.万古霉素药时曲线下面积给药与谷浓度目标值给药在肥胖与非肥胖耐甲氧西林金黄色葡萄球菌菌血症患者中的比较。
Ann Pharmacother. 2020 Jul;54(7):644-651. doi: 10.1177/1060028019897100. Epub 2019 Dec 30.
6
Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.万古霉素谷浓度与儿童耐甲氧西林金黄色葡萄球菌菌血症持续时间的关系。
J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):338-341. doi: 10.1093/jpids/pix068.
7
Evaluation of vancomycin serum trough concentrations and outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.耐甲氧西林金黄色葡萄球菌菌血症中万古霉素血清谷浓度及转归的评估
Int J Antimicrob Agents. 2012 Nov;40(5):474-5. doi: 10.1016/j.ijantimicag.2012.06.020. Epub 2012 Aug 9.
8
Optimization of vancomycin dosing in very low-birth-weight preterm neonates.极低出生体重早产儿万古霉素给药方案的优化
Am J Perinatol. 2015 Jan;32(1):83-6. doi: 10.1055/s-0034-1376183. Epub 2014 May 16.
9
Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients.耐甲氧西林金黄色葡萄球菌菌血症患者中基于万古霉素单谷浓度曲线下面积估算值与治疗结果的关联
Anaesthesiol Intensive Ther. 2019;51(3):218-223. doi: 10.5114/ait.2019.87362.
10
Outcomes associated with AUC24/MIC nomogram dosing of vancomycin.与万古霉素AUC24/MIC列线图给药相关的结果。
Ann Pharmacother. 2011 May;45(5):687-9. doi: 10.1345/aph.1P495. Epub 2011 Apr 26.
引用本文的文献
1
Factors affecting free vancomycin concentration and target attainment of free area under the concentration-time curve.影响游离万古霉素浓度及浓度-时间曲线下游离面积目标达成的因素。
J Pharm Health Care Sci. 2025 Feb 18;11(1):13. doi: 10.1186/s40780-025-00419-4.
2
Mathematical Albumin Function for Neonates Undergoing Therapeutic Hypothermia in Comparison with Control Neonates.接受治疗性低温治疗的新生儿与对照新生儿的数学白蛋白功能
J Clin Pharmacol. 2025 Jul;65(7):923-932. doi: 10.1002/jcph.70003. Epub 2025 Feb 11.
3
Real-Life Vancomycin Therapeutic Drug Monitoring in Coagulase-Negative Staphylococcal Bacteremia in Neonatal and Pediatric Intensive Care Unit: Are We Underestimating Augmented Renal Clearance?新生儿及儿科重症监护病房凝固酶阴性葡萄球菌血症中万古霉素的实际治疗药物监测：我们是否低估了增强的肾脏清除率？
Antibiotics (Basel). 2023 Oct 26;12(11):1566. doi: 10.3390/antibiotics12111566.
4
Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants.新生儿重症监护病房使用的抗生素的发育药代动力学：关注早产儿。
Biomedicines. 2023 Mar 17;11(3):940. doi: 10.3390/biomedicines11030940.
5
Use of Antibiotics in Preterm Newborns.早产儿抗生素的使用
Antibiotics (Basel). 2022 Aug 23;11(9):1142. doi: 10.3390/antibiotics11091142.
6
Population Pharmacokinetics of Vancomycin in Pregnant Women.万古霉素在孕妇中的群体药代动力学。
Front Pharmacol. 2022 Jun 6;13:873439. doi: 10.3389/fphar.2022.873439. eCollection 2022.
7
Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units.新生儿重症监护病房万古霉素给药剂量及治疗药物监测实践的差异。
Int J Clin Pharm. 2022 Apr;44(2):564-569. doi: 10.1007/s11096-021-01345-9. Epub 2021 Nov 2.
8
Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients.基于模型的优化儿童患者头孢托罗匹酯剂量的方法。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0120621. doi: 10.1128/AAC.01206-21. Epub 2021 Aug 16.
9
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper.发育药理学的现有知识、挑战与创新：连接儿童专家小组和欧洲发育、围产期和儿科药理学学会白皮书。
Br J Clin Pharmacol. 2022 Dec;88(12):4965-4984. doi: 10.1111/bcp.14958. Epub 2021 Jul 23.
10
Stratified Management for Bacterial Infections in Late Preterm and Term Neonates: Current Strategies and Future Opportunities Toward Precision Medicine.晚期早产儿和足月儿细菌感染的分层管理：精准医学的当前策略与未来机遇
Front Pediatr. 2021 Apr 1;9:590969. doi: 10.3389/fped.2021.590969. eCollection 2021.
本文引用的文献
1
Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.个体数据的群体药代动力学荟萃分析，旨在设计万古霉素在新生儿和婴幼儿中的首次随机疗效试验。
J Antimicrob Chemother. 2019 Aug 1;74(8):2128-2138. doi: 10.1093/jac/dkz158.
2
Factors impacting unbound vancomycin concentrations in neonates and young infants.影响新生儿和婴儿游离万古霉素浓度的因素。
Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1503-1510. doi: 10.1007/s10096-018-3277-8. Epub 2018 May 16.
3
Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?新生儿凝固酶阴性葡萄球菌败血症：我们是否需要调整万古霉素剂量或治疗目标？
BMC Pediatr. 2016 Dec 8;16(1):206. doi: 10.1186/s12887-016-0753-0.
4
Unanswered Questions Regarding Optimal Pediatric Vancomycin Use.
Ther Drug Monit. 2016 Jun;38(3):419-20. doi: 10.1097/FTD.0000000000000289.
5
Duration of vancomycin treatment for coagulase-negative Staphylococcus sepsis in very low birth weight infants.万古霉素治疗极低出生体重儿凝固酶阴性葡萄球菌败血症的疗程。
Br J Clin Pharmacol. 2013 Jul;76(1):58-64. doi: 10.1111/bcp.12053.
6
External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.新生儿万古霉素群体药代动力学模型的外部评估：已发表模型在不同临床环境中的可转移性。
Br J Clin Pharmacol. 2013 Apr;75(4):1068-80. doi: 10.1111/j.1365-2125.2012.04406.x.
7
Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration.新生儿抗菌药物的使用：万古霉素给药 50 年的经验。
Semin Fetal Neonatal Med. 2013 Feb;18(1):28-34. doi: 10.1016/j.siny.2012.10.003. Epub 2012 Nov 6.
8
Renal drug clearance in preterm neonates: relation to prenatal growth.早产儿的肾脏药物清除率：与产前生长的关系。
Ther Drug Monit. 2007 Jun;29(3):284-91. doi: 10.1097/FTD.0b013e31806db3f5.
9
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.万古霉素及其他抗菌药物在金黄色葡萄球菌下呼吸道感染患者中的药效学
Clin Pharmacokinet. 2004;43(13):925-42. doi: 10.2165/00003088-200443130-00005.
Zotero 插件